All Title Author
Keywords Abstract

Diseases  2013 

Effect of Cardio-Metabolic Risk Factors Clustering with or without Arterial Hypertension on Arterial Stiffness: A Narrative Review

DOI: 10.3390/diseases1010051

Keywords: metabolic syndrome, arterial stiffness, central aortic pressure, arterial hypertension, cardiovascular disease, type 2 diabetes mellitus, chronic kidney disease, hyperuricaemia, non alcoholic fatty liver disease, obstructive sleep apnea

Full-Text   Cite this paper   Add to My Lib


The clustering of cardio-metabolic risk factors, either when called metabolic syndrome (MetS) or not, substantially increases the risk of cardiovascular disease (CVD) and causes mortality. One of the possible mechanisms for this clustering's adverse effect is an increase in arterial stiffness (AS), and in high central aortic blood pressure (CABP), which are significant and independent CVD risk factors. Arterial hypertension was connected to AS long ago; however, other MetS components (obesity, dyslipidaemia, dysglycaemia) or MetS associated abnormalities not included in MetS diagnostic criteria (renal dysfunction, hyperuricaemia, hypercoaglutability, menopause, non alcoholic fatty liver disease, and obstructive sleep apnea) have been implicated too. We discuss the evidence connecting these cardio-metabolic risk factors, which negatively affect AS and finally increase CVD risk. Furthermore, we discuss the impact of possible lifestyle and pharmacological interventions on all these cardio-metabolic risk factors, in an effort to reduce CVD risk and identify features that should be taken into consideration when treating MetS patients with or without arterial hypertension.


[1]  Laurent, S.; Alivon, M.; Beaussier, H.; Boutouyrie, P. Aortic stiffness as a tissue biomarker for predicting future cardiovascular events in asymptomatic hypertensive subjects. Ann. Med. 2012, 44 Suppl 1, S93–S97.
[2]  Palatini, P.; Casiglia, E.; G?sowski, J.; G?uszek, J.; Jankowski, P.; Narkiewicz, K.; Saladini, F.; Stolarz-Skrzypek, K.; Tikhonoff, V.; Van Bortel, L.; et al. Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension. Vasc. Health. Risk. Manag. 2011, 7, 725–739.
[3]  Meaume, S.; Benetos, A.; Henry, O.F.; Rudnichi, A.; Safar, M.E. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 2046–2050, doi:10.1161/hq1201.100226.
[4]  Boutouyrie, P.; Tropeano, A.I.; Asmar, R.; Gautier, I.; Benetos, A.; Lacolley, P.; Laurent, S. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002, 39, 10–15, doi:10.1161/hy0102.099031.
[5]  Vlachopoulos, C.; Aznaouridis, K.; O'Rourke, M.F.; Safar, M.E.; Baou, K.; Stefanadis, C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur. Heart J. 2010, 31, 1865–1871, doi:10.1093/eurheartj/ehq024.
[6]  Antonini-Canterin, F.; Carerj, S.; Di Bello, V.; Di Salvo, G.; La Carrubba, S.; Vriz, O.; Pavan, D.; Balbarini, A.; Nicolosi, G.L.; Research Group of the Italian Society of Cardiovascular Echography (SIEC). Arterial stiffness and ventricular stiffness: a couple of diseases or a coupling disease? A review from the cardiologist's point of view. Eur. J. Echocardiogr. 2009, 10, 36–43, doi:10.1093/ejechocard/jen236.
[7]  Vlachopoulos, C.; Alexopoulos, N.; Stefanadis, C. Aortic stiffness: Prime time for integration into clinical practice? Hellenic J. Cardiol. 2010, 51, 385–390.
[8]  Sassalos, K.; Vlachopoulos, C.; Alexopoulos, N.; Gialernios, T.; Aznaouridis, K.; Stefanadis, C. The acute and chronic effect of cigarette smoking on the elastic properties of the ascending aorta in healthy male subjects. Hellenic J. Cardiol. 2006, 47, 263–268.
[9]  Cruickshank, K.; Riste, L.; Anderson, S.G.; Wright, J.S.; Dunn, G.; Gosling, R.G. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002, 106, 2085–2090, doi:10.1161/01.CIR.0000033824.02722.F7.
[10]  Vlachopoulos, C.; O'rourke, M. Genesis of the normal and abnormal arterial pulse. Curr. Probl. Cardiol. 2000, 25, 303–367, doi:10.1067/mcd.2000.104057.
[11]  Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur. Heart J. 2010, 31, 2338–2350, doi:10.1093/eurheartj/ehq165.
[12]  Sugawara, J.; Hayashi, K.; Yokoi, T.; Cortez-Cooper, M.Y.; DeVan, A.E.; Anton, M.A.; Tanaka, H. Brachial-ankle pulse wave velocity: an index of central arterial stiffness? J. Hum. Hypertens. 2005, 19, 401–406, doi:10.1038/sj.jhh.1001838.
[13]  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285, 2486–2497, doi:10.1001/jama.285.19.2486.
[14]  Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.; Loria, C.M.; Smith, S.C.; et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640–1645, doi:10.1161/CIRCULATIONAHA.109.192644.
[15]  Lakka, H.M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J.; Salonen, J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288, 2709–2716, doi:10.1001/jama.288.21.2709.
[16]  Ford, E.S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004, 173, 309–314.
[17]  Kahn, R. Metabolic syndrome--what is the clinical usefulness? Lancet 2008, 371, 1892–1893, doi:10.1016/S0140-6736(08)60731-X.
[18]  Kahn, R.; Buse, J.; Ferrannini, E.; Stern, M.; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28, 2289–2304, doi:10.2337/diacare.28.9.2289.
[19]  IDF Consensus Worldwide Definition of the Metabolic Syndrome. Available online: Http:// Meta def_final.Pdf (accessed on 18 November 2013).
[20]  Benetos, A.; Rudnichi, A.; Safar, M.; Guize, L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998, 32, 560–564, doi:10.1161/01.HYP.32.3.560.
[21]  Nakanishi, N.; Suzuki, K.; Tatara, K. Clustered features of the metabolic syndrome and the risk for increased aortic pulse wave velocity in middle-aged Japanese men. Angiology 2003, 54, 551–559, doi:10.1177/000331970305400504.
[22]  Brillante, D.G.; O'Sullivan, A.J.; Howes, L.G. Arterial stiffness in insulin resistance: the role of nitric oxide and angiotensin II receptors. Vasc. Health Risk. Manag. 2009, 5, 73–78.
[23]  Sengstock, D.M.; Vaitkevicius, P.V.; Supiano, M.A. Arterial stiffness is related to insulin resistance in nondiabetic hypertensive older adults. J. Clin. Endocrinol. MeTable 2005, 90, 2823–2827, doi:10.1210/jc.2004-1686.
[24]  Seo, H.S.; Kang, T.S.; Park, S.; Park, H.Y.; Ko, Y.G.; Choi, D.; Jang, Y.; Chung, N. Insulin resistance is associated with arterial stiffness in nondiabetic hypertensives independent of metabolic status. Hypertens. Res. 2005, 28, 945–951, doi:10.1291/hypres.28.945.
[25]  Coutinho, M.; Gerstein, H.C.; Wang, Y.; Yusuf, S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22, 233–240, doi:10.2337/diacare.22.2.233.
[26]  DECODE Study Group, t. E.D. E.G. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 2001, 161, 397–405, doi:10.1001/archinte.161.3.397.
[27]  De Angelis, L.; Millasseau, S.C.; Smith, A.; Viberti, G.; Jones, R.H.; Ritter, J.M.; Chowienczyk, P.J. Sex differences in age-related stiffening of the aorta in subjects with type 2 diabetes. Hypertension 2004, 44, 67–71, doi:10.1161/01.HYP.0000130482.81883.fd.
[28]  Ohnishi, H.; Saitoh, S.; Takagi, S.; Ohata, J.; Isobe, T.; Kikuchi, Y.; Takeuchi, H.; Shimamoto, K. Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study. Diabetes Care 2003, 26, 437–440, doi:10.2337/diacare.26.2.437.
[29]  Ahluwalia, N.; Drouet, L.; Ruidavets, J.B.; Perret, B.; Amar, J.; Boccalon, H.; Hanaire-Broutin, H.; Ferrières, J. Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis 2006, 186, 345–353, doi:10.1016/j.atherosclerosis.2005.07.021.
[30]  Ferreira, I.; Boreham, C.A.; Twisk, J.W.; Gallagher, A.M.; Young, I.S.; Murray, L.J.; Stehouwer, C.D. Clustering of metabolic syndrome risk factors and arterial stiffness in young adults: the Northern Ireland Young Hearts Project. J. Hypertens. 2007, 25, 1009–1020, doi:10.1097/HJH.0b013e3280a94e76.
[31]  Inoue, N.; Maeda, R.; Kawakami, H.; Shokawa, T.; Yamamoto, H.; Ito, C.; Sasaki, H. Aortic pulse wave velocity predicts cardiovascular mortality in middle-aged and elderly Japanese men. Circ. J. 2009, 73, 549–553, doi:10.1253/circj.CJ-08-0492.
[32]  Shin, J.Y.; Lee, H.R.; Lee, D.C. Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes. Cardiovasc. Diabetol. 2011, 10, 30–34, doi:10.1186/1475-2840-10-30.
[33]  Webb, D.R.; Khunti, K.; Silverman, R.; Gray, L.J.; Srinivasan, B.; Lacy, P.S.; Williams, B.; Davies, M.J. Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. Diabetologia 2010, 53, 1190–1198, doi:10.1007/s00125-010-1689-9.
[34]  Park, J.S.; Nam, J.S.; Cho, M.H.; Yoo, J.S.; Ahn, C.W.; Jee, S.H.; Lee, H.S.; Cha, B.S.; Kim, K.R.; Lee, H.C. Insulin resistance independently influences arterial stiffness in normoglycemic normotensive postmenopausal women. Menopause 2010, 17, 779–784.
[35]  Simkova, A.; Bulas, J.; Balogova, S.; Reptova, A.; Kisa, B.; Luha, J.; Kinova, S. Metabolic syndrome and its effect on aortic stiffness in premenopausal women. Bratisl. Lek. Listy. 2013, 114, 279–282.
[36]  Thomas, G.; Sehgal, A.R.; Kashyap, S.R.; Srinivas, T.R.; Kirwan, J.P.; Navaneethan, S.D. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 2011, 6, 2364–2373, doi:10.2215/CJN.02180311.
[37]  Katsiki, N.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. Characteristics Other Than the Diagnostic Criteria Associated with Metabolic Syndrome: an Overview. Curr. Vasc. Pharmacol. 2013. in press.
[38]  Wilson, A.C.; Mitsnefes, M.M. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am. J. Kidney Dis. 2009, 54, 345–360, doi:10.1053/j.ajkd.2009.04.027.
[39]  Shoji, T.; Abe, T.; Matsuo, H.; Egusa, G.; Yamasaki, Y.; Kashihara, N.; Shirai, K.; Kashiwagi, A. Committee of Renal and Peripheral Arteries, Japan Atherosclerosis. J. Atheroscler. Thromb. 2012, 19, 299–315, doi:10.5551/jat.10454.
[40]  Athyros, V.G.; Mikhailidis, D.P.; Liberopoulos, E.N.; Kakafika, A.I.; Karagiannis, A.; Papageorgiou, A.A.; Tziomalos, K.; Ganotakis, E.S.; Elisaf, M. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol. Dial. Transplant. 2007, 22, 118–127.
[41]  Athyros, V.G.; Mikhailidis, D.P.; Papageorgiou, A.A.; Symeonidis, A.N.; Pehlivanidis, A.N.; Bouloukos, V.I.; Elisaf, M. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J. Clin. Pathol. 2004, 57, 728–734, doi:10.1136/jcp.2003.012989.
[42]  Athyros, V.G.; Karagiannis, A.; Katsiki, N.; Mikhailidis, D.P. Statins in patients with renal dysfunction. Am. J. Cardiol. 2012, 109, 1537–1537.
[43]  Athyros, V.G.; Hatzitolios, A.I.; Karagiannis, A.; Savopoulos, C.; Katsiki, N.; Tziomalos, K.; Papagianni, A.; Kakafika, A.; Gossios, T.D.; Mikhailidis, D.P. Group, Improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. the imperative renal analysis. Arch. Med. Sci. 2011, 7, 984–992.
[44]  Athyros, V.G.; Karagiannis, A.; Ganotakis, E.S.; Paletas, K.; Nicolaou, V.; Bacharoudis, G.; Tziomalos, K.; Alexandrides, T.; Liberopoulos, E.N.; Mikhailidis, D.P.; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr. Med. Res. Opin. 2011, 27, 1659–1668, doi:10.1185/03007995.2011.595782.
[45]  Safar, M.E.; London, G.M.; Plante, G.E. Arterial stiffness and kidney function. Hypertension 2004, 43, 163–168, doi:10.1161/01.HYP.0000114571.75762.b0.
[46]  Katsiki, N.; Koumaras, C.; Athyros, V.G.; Karagiannis, A. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 2012, 63, 9–11, doi:10.1177/0003319711406256.
[47]  Koumaras, C.; Tzimou, M.; Stavrinou, E.; Griva, T.; Gossios, T.D.; Katsiki, N.; Athyros, V.G.; Mikhailidis, D.P.; Karagiannis, A. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. Am. J. Cardiovasc. Drugs 2012, 12, 143–156, doi:10.2165/11599040-000000000-00000.
[48]  Kanaki, A.I.; Sarafidis, P.A.; Georgianos, P.I.; Kanavos, K.; Tziolas, I.M.; Zebekakis, P.E.; Lasaridis, A.N. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am. J. Hypertens. 2013, 26, 608–616, doi:10.1093/ajh/hps098.
[49]  Sadat, U.; Howarth, S.P.; Usman, A.; Taviani, V.; Tang, T.Y.; Graves, M.J.; Gillard, J.H. Effect of low-and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging -a post-hoc sub group analysis of ATHEROMA (Atorvastatin Therapy: Effects On Reduction Of Macrophage Activity) Study. J. Atheroscler. Thromb. 2013, 20, 46–56, doi:10.5551/jat.12633.
[50]  Athyros, V.G.; Karagiannis, A.; Kakafika, A.; Elisaf, M.; Mikhailidis, D.P. Statins and renal function. Is the compound and dose making a difference? Nephrol. Dial. Transplant. 2007, 22, 963–964.
[51]  Katsiki, N.; Karagiannis, A.; Athyros, V.G.; Mikhailidis, D.P. Hyperuricaemia: more than just a cause of gout? J. Cardiovasc. Med. (Hagerstown) 2003, 14, 397–402.
[52]  Tsouli, S.G.; Liberopoulos, E.N.; Mikhailidis, D.P.; Athyros, V.G.; Elisaf, M.S. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006, 55, 1293–1301, doi:10.1016/j.metabol.2006.05.013.
[53]  Bickel, C.; Rupprecht, H.J.; Blankenberg, S.; Rippin, G.; Hafner, G.; Daunhauer, A.; Hofmann, K.P.; Meyer, J. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am. J. Cardiol. 2002, 89, 12–17.
[54]  Hsu, P.F.; Chuang, S.Y.; Cheng, H.M.; Sung, S.H.; Ting, C.T.; Lakatta, E.G.; Yin, F.C.; Chou, P.; Chen, C.H. Associations of serum uric acid levels with arterial wave reflections and central systolic blood pressure. Int. J. Cardiol. 2013, 168, 2057–2063, doi:10.1016/j.ijcard.2013.01.164.
[55]  Ishizaka, N.; Ishizaka, Y.; Toda, E.; Hashimoto, H.; Nagai, R.; Yamakado, M. Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis 2007, 192, 131–137, doi:10.1016/j.atherosclerosis.2006.04.016.
[56]  Park, J.S.; Kang, S.; Ahn, C.W.; Cha, B.S.; Kim, K.R.; Lee, H.C. Relationships between serum uric acid, Adiponectin and arterial stiffness in postmenopausal women. Maturitas 2012, 73, 344–348, doi:10.1016/j.maturitas.2012.09.009.
[57]  Bian, S.; Guo, H.; Ye, P.; Luo, L.; Wu, H.; Xiao, W. Serum uric Acid level and diverse impacts on regional arterial stiffness and wave reflection. Iran. J. Public Health 2012, 41, 33–41.
[58]  Shin, J.Y.; Lee, H.R.; Shim, J.Y. Significance of high-normal serum uric acid level as a risk factor for arterial stiffness in healthy Korean men. Vasc. Med. 2012, 17, 37–43, doi:10.1177/1358863X11434197.
[59]  Khoshdel, A.R.; Carney, S.L.; Gillies, A. Circulatory syndrome: an evolution of the metabolic syndrome concept! Curr. Cardiol. Rev. 2012, 8, 68–76, doi:10.2174/157340312801215773.
[60]  Devaraj, S.; Rosenson, R.S.; Jialal, I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol. Metab. Clin. North Am. 2004, 33, 431–453, doi:10.1016/j.ecl.2004.03.008.
[61]  Nieuwdorp, M.; Stroes, E.S.; Meijers, J.C.; Büller, H. Hypercoagulability in the metabolic syndrome. Curr. Opin. Pharmacol. 2005, 5, 155–159, doi:10.1016/j.coph.2004.10.003.
[62]  Sagastagoitia, J.D.; Sáez, Y.; Vacas, M.; Narváez, I.; Sáez de Lafuente, J.P.; Molinero, E.; Magro, A.; Lafita, M.; Santos, M.; Escobar, A.; et al. Association between inflammation, lipid and hemostatic factors in patients with stable angina. Thromb. Res. 2007, 120, 53–59, doi:10.1016/j.thromres.2006.06.013.
[63]  Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346, 1221–1231, doi:10.1056/NEJMra011775.
[64]  Lee, Y.J.; Shim, J.Y.; Moon, B.S.; Shin, Y.H.; Jung, D.H.; Lee, J.H.; Lee, H.R. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig. Dis. Sci. 2012, 57, 196–203, doi:10.1007/s10620-011-1819-3.
[65]  Salvi, P.; Ruffini, R.; Agnoletti, D.; Magnani, E.; Pagliarani, G.; Comandini, G.; Praticò, A.; Borghi, C.; Benetos, A.; Pazzi, P. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J. Hypertens. 2010, 28, 1699–1707, doi:10.1097/HJH.0b013e32833a7de6.
[66]  Kim, B.J.; Kim, N.H.; Kim, B.S.; Kang, J.H. The association between nonalcoholic fatty liver disease, metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals. Cardiology 2012, 123, 54–61, doi:10.1159/000341248.
[67]  Wilkinson, I.; Cockcroft, J.R. Cholesterol, Lipids and arterial stiffness. Adv. Cardiol. 2007, 44, 261–277, doi:10.1159/000096747.
[68]  Matsuo, T.; Iwade, K.; Hirata, N.; Yamashita, M.; Ikegami, H.; Tanaka, N.; Aosaki, M.; Kasanuki, H. Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels 2005, 20, 8–12, doi:10.1007/s00380-004-0793-5.
[69]  Wang, F.; Ye, P.; Luo, L.; Xiao, W.; Qi, L.; Bian, S.; Wu, H.; Sheng, L.; Xiao, T.; Xu, R. Association of serum lipids with arterial stiffness in a population-based study in Beijing. Eur. J. Clin. Invest. 2011, 41, 929–936, doi:10.1111/j.1365-2362.2011.02481.x.
[70]  van den Bogaard, B.; Holleboom, A.G.; Duivenvoorden, R.; Hutten, B.A.; Kastelein, J.J.; Hovingh, G.K.; Kuivenhoven, J.A.; Stroes, E.S.; van den Born, B.J. Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. Atherosclerosis 2012, 225, 481–485, doi:10.1016/j.atherosclerosis.2012.09.022.
[71]  Urbina, E.M.; Khoury, P.R.; McCoy, C.E.; Dolan, L.M.; Daniels, S.R.; Kimball, T.R. Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents, and young adults. Pediatrics 2013, 131, e1082–e1090, doi:10.1542/peds.2012-1726.
[72]  Shimizu, Y.; Nakazato, M.; Sekita, T.; Kadota, K.; Yamasaki, H.; Takamura, N.; Aoyagi, K.; Maeda, T. Association of arterial stiffness and diabetes with triglycerides-to-HDL cholesterol ratio for Japanese men: The Nagasaki Islands Study. Atherosclerosis 2013, 228, 491–495, doi:10.1016/j.atherosclerosis.2013.03.021.
[73]  Wilkinson, I.B.; Prasad, K.; Hall, I.R.; Thomas, A.; MacCallum, H.; Webb, D.J.; Frenneaux, M.P.; Cockcroft, J.R. Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J. Am. Coll. Cardiol. 2002, 39, 1005–1011, doi:10.1016/S0735-1097(02)01723-0.
[74]  Litvin, A.; Sukmarova, Z.; Elfimova, E.; Aksenova, A.; Galitsin, P.; Rogoza, A.; Chazova, I. Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension. Vasc. Health. Risk Manag. 2013, 9, 229–235.
[75]  Somers, V.K.; White, D.P.; Amin, R.; Abraham, W.T.; Costa, F.; Culebras, A.; Daniels, S.; Floras, J.S.; Hunt, C.E.; Olson, L.J.; et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J. Am. Coll. Cardiol. 2008, 52, 686–717, doi:10.1016/j.jacc.2008.05.002.
[76]  Jones, A.; Vennelle, M.; Connell, M.; McKillop, G.; Newby, D.E.; Douglas, N.J.; Riha, R.L. Arterial stiffness and endothelial function in obstructive sleep apnoea/hypopnoea syndrome. Sleep Med. 2013, 14, 428–432, doi:10.1016/j.sleep.2013.01.001.
[77]  Marin, J.M.; Carrizo, S.J.; Vicente, E.; Agusti, A.G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005, 365, 1046–1053.
[78]  Buchner, N.J.; Quack, I.; Stegbauer, J.; Woznowski, M.; Kaufmann, A.; Rump, L.C. Treatment of obstructive sleep apnea reduces arterial stiffness. Sleep Breath. 2012, 16, 123–133, doi:10.1007/s11325-010-0465-x.
[79]  Vlachantoni, I.T.; Dikaiakou, E.; Antonopoulos, C.N.; Stefanadis, C.; Daskalopoulou, S.S.; Petridou, E.T. Effects of continuous positive airway pressure (CPAP) treatment for obstructive sleep apnea in arterial stiffness: a meta-analysis. Sleep Med. Rev. 2013, 17, 19–28, doi:10.1016/j.smrv.2012.01.002.
[80]  Kato, M.; Kumagai, T.; Naito, R.; Maeno, K.; Kasagi, S.; Kawana, F.; Ishiwata, S.; Narui, K.; Kasai, T. Change in cardio-ankle vascular index by long-term continuous positive airway pressure therapy for obstructive sleep apnea. J. Cardiol. 2011, 58, 74–82, doi:10.1016/j.jjcc.2011.03.005.
[81]  Sugawara, J.; Otsuki, T.; Tanabe, T.; Hayashi, K.; Maeda, S.; Matsuda, M. Physical activity duration, intensity, and arterial stiffening in postmenopausal women. Am. J. Hypertens. 2006, 19, 1032–1036, doi:10.1016/j.amjhyper.2006.03.008.
[82]  van de Laar, R.J.; Ferreira, I.; van Mechelen, W.; Prins, M.H.; Twisk, J.W.; Stehouwer, C.D. Lifetime vigorous but not light-to-moderate habitual physical activity impacts favorably on carotid stiffness in young adults: the Amsterdam growth and health longitudinal study. Hypertension 2010, 55, 33–39, doi:10.1161/HYPERTENSIONAHA.109.138289.
[83]  van de Laar, R.J.; Stehouwer, C.D.; van Bussel, B.C.; Prins, M.H.; Twisk, J.W.; Ferreira, I. Adherence to a Mediterranean dietary pattern in early life is associated with lower arterial stiffness in adulthood: the Amsterdam Growth and Health Longitudinal Study. J. Intern. Med. 2013, 273, 79–93, doi:10.1111/j.1365-2796.2012.02577.x.
[84]  van de Laar, R.J.; Stehouwer, C.D.; van Bussel, B.C.; te Velde, S.J.; Prins, M.H.; Twisk, J.W.; Ferreira, I. Lower lifetime dietary fiber intake is associated with carotid artery stiffness: the Amsterdam Growth and Health Longitudinal Study. Am. J. Clin. Nutr. 2012, 96, 14–23, doi:10.3945/ajcn.111.024703.
[85]  Lydakis, C.; Stefanaki, E.; Stefanaki, S.; Thalassinos, E.; Kavousanaki, M.; Lydaki, D. Correlation of blood pressure, obesity, and adherence to the Mediterranean diet with indices of arterial stiffness in children. Eur. J. Pediatr. 2012, 171, 1373–1382, doi:10.1007/s00431-012-1735-3.
[86]  Tzima, N.; Pitsavos, C.; Panagiotakos, D.B.; Skoumas, J.; Zampelas, A.; Chrysohoou, C.; Stefanadis, C. Mediterranean diet and insulin sensitivity, lipid profile and blood pressure levels, in overweight and obese people; the Attica study. Lipids Health Dis. 2007, 6, 22–28, doi:10.1186/1476-511X-6-22.
[87]  Desroches, S.; Lapointe, A.; Ratté, S.; Gravel, K.; Légaré, F.; Thirsk, J. Interventions to enhance adherence to dietary advice for preventing and managing chronic diseases in adults: a study protocol. BMC Public Health 2011, 11, 111–114, doi:10.1186/1471-2458-11-111.
[88]  Dudenbostel, T.; Glasser, S.P. Effects of antihypertensive drugs on arterial stiffness. Cardiol. Rev. 2012, 20, 259–263, doi:10.1097/CRD.0b013e31825d0a44.
[89]  Williams, B.; Lacy, P.S.; Thom, S.M.; Cruickshank, K.; Stanton, A.; Collier, D.; Hughes, A.D.; Thurston, H.; O'Rourke, M.; Investigators, C.; et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113, 1213–1225, doi:10.1161/CIRCULATIONAHA.105.595496.
[90]  Duprez, D.A. Is vascular stiffness a target for therapy? Cardiovasc. Drugs. Ther. 2010, 24, 305–310, doi:10.1007/s10557-010-6250-z.
[91]  Najjar, S.S.; Scuteri, A.; Shetty, V.; Wright, J.G.; Muller, D.C.; Fleg, J.L.; Spurgeon, H.P.; Ferrucci, L.; Lakatta, E.G. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J. Am. Coll. Cardiol. 2008, 51, 1377–1383, doi:10.1016/j.jacc.2007.10.065.
[92]  Jin, Y.; Thijs, L.; Richart, T.; Li, Y.; Dolan, E.; Wang, J.G.; Protogerou, A.; O'Brien, E.; Staessen, J.A.; Safar, M.E. Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs. Hypertens. Res. 2011, 34, 489–495, doi:10.1038/hr.2010.256.
[93]  Ng, K.; Butlin, M.; Avolio, A.P. Persistent effect of early, brief angiotensin-converting enzyme inhibition on segmental pressure dependency of aortic stiffness in spontaneously hypertensive rats. J. Hypertens. 2012, 30, 1782–1790, doi:10.1097/HJH.0b013e3283562e35.
[94]  Ong, K.T.; Delerme, S.; Pannier, B.; Safar, M.E.; Benetos, A.; Laurent, S.; Aoutouyrie, P. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J. Hypertens. 2011, 29, 1034–1042, doi:10.1097/HJH.0b013e328346a583.
[95]  Pende, A.; Dallegri, F. Renin-angiotensin antagonists: therapeutic effects beyond blood pressure control? Curr. Pharm. Des. 2012, 18, 1011–1020, doi:10.2174/138161212799436575.
[96]  Shahin, Y.; Khan, J.A.; Chetter, I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis 2012, 221, 18–33, doi:10.1016/j.atherosclerosis.2011.12.005.
[97]  Williams, B.; Lacy, P.S.; Cruickshank, J.K.; Collier, D.; Hughes, A.D.; Stanton, A.; Thom, S.; Thurston, H.; CAFE and ASCOT Investigators. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation 2009, 119, 53–61.
[98]  Hongo, M.; Kumazaki, S.; Izawa, A.; Hidaka, H.; Tomita, T.; Yazaki, Y.; Kinoshita, O.; Ikeda, U. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group. Circ. J. 2011, 75, 2660–2667, doi:10.1253/circj.CJ-11-0497.
[99]  Hongo, M.; Tsutsui, H.; Mawatari, E.; Hidaka, H.; Kumazaki, S.; Yazaki, Y.; Takahashi, M.; Kinoshita, O.; Ikeda, U. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Circ. J. 2008, 72, 722–728, doi:10.1253/circj.72.722.
[100]  Kontopoulos, A.G.; Athyros, V.G.; Pehlivanidis, A.N.; Demitriadis, D.S.; Papageorgiou, A.A.; Boudoulas, H. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr. Med. Res. Opin. 2003, 19, 22–27, doi:10.1185/030079902125001290.
[101]  Igase, M.; Kohara, K.; Tabara, Y.; Nagai, T.; Ochi, N.; Kido, T.; Ochi, M.; Miki, T. Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia. Menopause 2012, 19, 1294–1299, doi:10.1097/gme.0b013e318259c04e.
[102]  Fassett, R.G.; Robertson, I.K.; Ball, M.J.; Geraghty, D.P.; Sharman, J.E.; Coombes, J.S. Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. J. Atheroscler. Thromb. 2010, 17, 235–241, doi:10.5551/jat.2683.
[103]  Orr, J.S.; Dengo, A.L.; Rivero, J.M.; Davy, K.P. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension 2009, 54, 763–768, doi:10.1161/HYPERTENSIONAHA.109.138248.
[104]  Mukherjee, S.; Mukhopadhyay, P.; Pandit, K.; Chowdhury, S. Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes. J. Indian. Med. Assoc. 2008, 106, 716–719.
[105]  Haller, M.J.; Stein, J.M.; Shuster, J.J.; Theriaque, D.; Samyn, M.M.; Pepine, C.; Silverstein, J.H. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J. Pediatr. Endocrinol. MeTable 2009, 22, 65–68.
[106]  Lunder, M.; Jani?, M.; Habjan, S.; Sabovi?, M. Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males--a pilot study. Atherosclerosis 2011, 215, 446–451, doi:10.1016/j.atherosclerosis.2010.12.041.
[107]  Tam, L.S.; Li, E.K.; Shang, Q.; Tomlinson, B.; Lee, V.W.; Lee, K.K.; Li, M.; Kuan, W.P.; Li, T.K.; Tseung, L.; et al. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scand. J. Rheumatol. 2011, 40, 411–421, doi:10.3109/03009742.2011.586649.
[108]  Wang, J.; Xu, J.; Zhou, C.; Zhang, Y.; Xu, D.; Guo, Y.; Yang, Z. Improvement of arterial stiffness by reducing oxidative stress damage in elderly hypertensive patients after 6 months of atorvastatin therapy. J. Clin. Hypertens. (Greenwich) 2012, 14, 245–249.
[109]  Toyama, K.; Sugiyama, S.; Oka, H.; Iwasaki, Y.; Sumida, H.; Tanaka, T.; Tayama, S.; Jinnouchi, H.; Ogawa, H. Combination treatment of rosuvastatin or atorvastatin, with regular exercise improves arterial wall stiffness in patients with coronary artery disease. PLoS One 2012, 7, e41369–e41376.
[110]  Duleba, A.J. Medical management of metabolic dysfunction in PCOS. Steroids 2012, 77, 306–311, doi:10.1016/j.steroids.2011.11.014.
[111]  Agarwal, N.; Rice, S.P.; Bolusani, H.; Luzio, S.D.; Dunseath, G.; Ludgate, M.; Rees, D.A. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, Placebo-controlled, Crossover trial. J. Clin. Endocrinol. MeTable 2010, 95, 722–730, doi:10.1210/jc.2009-1985.
[112]  Kaya, M.G.; Calapkorur, B.; Karaca, Z.; Yildirim, S.; Celik, A.; Akpek, M.; Unluhizarci, K.; Kelestimur, F. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf) 2012, 77, 885–892, doi:10.1111/j.1365-2265.2012.04436.x.
[113]  Meaney, E.; Vela, A.; Samaniego, V.; Meaney, A.; Asbún, J.; Zempoalteca, J.C.; Elisa, Z.N.; Emma, M.N.; Guzman, M.; Hicks, J.; et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin. Exp. Pharmacol. Physiol. 2008, 35, 895–903, doi:10.1111/j.1440-1681.2008.04920.x.
[114]  Araki, T.; Emoto, M.; Teramura, M.; Yokoyama, H.; Mori, K.; Hatsuda, S.; Maeno, T.; Shinohara, K.; Koyama, H.; Shoji, T.; Inaba, M.; Nishizawa, Y. Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. Metabolism 2006, 55, 996–1001, doi:10.1016/j.metabol.2006.03.008.
[115]  Kiyici, S.; Ersoy, C.; Kaderli, A.; Fazlioglu, M.; Budak, F.; Duran, C.; Gul, O.O.; Sigirli, D.; Baran, I.; Tuncel, E.; et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Res. Clin. Pract. 2009, 86, 44–50, doi:10.1016/j.diabres.2009.07.004.
[116]  Forst, T.; Michelson, G.; Ratter, F.; Weber, M.M.; Anders, S.; Mitry, M.; Wilhelm, B.; Pfützner, A. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet. Med. 2012, 29, 1115–1118.
[117]  Koren, S.; Shemesh-Bar, L.; Tirosh, A.; Peleg, R.K.; Berman, S.; Hamad, R.A.; Vinker, S.; Golik, A.; Efrati, S. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol. Ther. 2012, 14, 561–567, doi:10.1089/dia.2011.0296.
[118]  Shargorodsky, M.; Omelchenko, E.; Matas, Z.; Boaz, M.; Gavish, D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovasc. Diabetol. 2012, 11, 61–68, doi:10.1186/1475-2840-11-61.
[119]  Bibra, H.; Siegmund, T.; Ceriello, A.; Volozhyna, M.; Schumm-Draeger, P.M. Optimized postprandial glucose control is associated with improved cardiac/vascular function—comparison of three insulin regimens in well-controlled type 2 diabetes. Horm. Metab. Res. 2009, 41, 109–115.
[120]  Ohira, M.; Endo, K.; Oyama, T.; Yamaguchi, T.; Ban, N.; Kawana, H.; Nagayama, D.; Nagumo, A.; Saiki, A.; Murano, T.; et al. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism 2011, 60, 78–85, doi:10.1016/j.metabol.2010.06.001.
[121]  Athyros, V.G.; Mikhailidis, D.P.; Papageorgiou, A.A.; Bouloukos, V.I.; Pehlivanidis, A.N.; Symeonidis, A.N.; Elisaf, M.; Group, G.S.C. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J. Hum. Hypertens. 2004, 18, 781–788, doi:10.1038/sj.jhh.1001748.
[122]  Athyros, V.G.; Mikhailidis, D.P.; Papageorgiou, A.A.; Bouloukos, V.I.; Pehlivanidis, A.N.; Symeonidis, A.N.; Kakafika, A.I.; Daskalopoulou, S.S.; Elisaf, M. Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets 2005, 16, 65–71, doi:10.1080/09537100400009321.


comments powered by Disqus